| P50 | author | Yasmin A Rawlins | Q88137268 |
| | Christopher C Denton | Q89569219 |
| | Matthew J. Oberley | Q37389393 |
| | Etan Orgel | Q57047965 |
| P2093 | author name string | Deepa Bhojwani | |
| P2860 | cites work | Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing | Q24632749 |
| | A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL) | Q24633382 |
| | The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia | Q26744280 |
| | Acute pancreatitis as a complication of childhood cancer treatment | Q26766231 |
| | Hepatotoxicity Secondary to Chemotherapy | Q26861560 |
| | Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction | Q27023839 |
| | Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration | Q28087637 |
| | Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial | Q29038010 |
| | 2000 CDC Growth Charts for the United States: methods and development | Q29614506 |
| | Nonalcoholic fatty liver disease in adolescents and young adults: The next frontier in the epidemic | Q30238933 |
| | Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434 | Q30300395 |
| | Hepatic dysfunction as the presenting feature of acute lymphoblastic leukemia | Q32054052 |
| | Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. | Q32061751 |
| | Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial | Q33388076 |
| | Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy. | Q33557148 |
| | Hepato-biliary late effects in survivors of childhood and adolescent cancer: a report from the Children's Oncology Group | Q33729370 |
| | Hepatotoxicity of chemotherapy | Q33942794 |
| | Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols | Q79843503 |
| | Acute lymphoblastic leukemia presenting in fulminant hepatic failure | Q81075402 |
| | Long-term follow-up of children with 6-thioguanine-related chronic hepatoxicity following treatment for acute lymphoblastic leukaemia | Q84436276 |
| | Body mass index and the risk and prognosis of acute pancreatitis: a meta-analysis | Q84920565 |
| | Weight patterns in children with higher risk ALL: A report from the Children's Oncology Group (COG) for CCG 1961. | Q34603282 |
| | Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy | Q34830088 |
| | Weight change during childhood acute lymphoblastic leukemia induction therapy predicts obesity: a report from the Children's Oncology Group | Q35007811 |
| | Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia | Q35616085 |
| | Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. | Q35976588 |
| | Prognostic significance of hepatotoxicity during maintenance chemotherapy for childhood acute lymphoblastic leukaemia | Q35982421 |
| | Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group | Q36058255 |
| | Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group | Q36478435 |
| | Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group | Q36695870 |
| | Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study | Q36713493 |
| | Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study | Q36713502 |
| | Asparaginase-associated toxicity in children with acute lymphoblastic leukemia | Q36762608 |
| | Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia | Q37130123 |
| | Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232 | Q37169331 |
| | Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis | Q37291435 |
| | Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia | Q37319370 |
| | Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia. | Q37385443 |
| | Limitations of body mass index to assess body composition due to sarcopenic obesity during leukemia therapy | Q37716294 |
| | Non-alcoholic fatty liver disease fibrosis score predicts hematological toxicity of chemotherapy including irinotecan for colorectal cancer | Q37732059 |
| | Asparaginase-associated pancreatitis in children | Q38036389 |
| | Predicting relapse risk in childhood acute lymphoblastic leukaemia | Q38117685 |
| | Toxicity of Cancer Therapy in Adolescents and Young Adults (AYAs). | Q38554109 |
| | Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus | Q38864711 |
| | A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1. | Q39684863 |
| | Abnormal liver transaminases and conjugated hyperbilirubinemia at presentation of acute lymphoblastic leukemia. | Q42958220 |
| | Acute pancreatitis in children with acute lymphoblastic leukemia after chemotherapy | Q44663071 |
| | Liver transplantation in an adolescent with acute liver failure from acute lymphoblastic leukemia. | Q44915988 |
| | Late effects in long-term survivors after treatment for childhood acute leukemia | Q45057213 |
| | Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. | Q46540888 |
| | Genome-Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy | Q46844249 |
| | Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule | Q48590767 |
| | Hepatotoxicity in the treatment of acute lymphoblastic leukaemia | Q66869985 |
| | Hepatic fibrosis in children with acute leukemia.A complication of therapy | Q78779504 |
| P433 | issue | 3 | |
| P921 | main subject | hepatotoxicity | Q1349821 |
| | lymphoblastic leukemia | Q18553852 |
| P577 | publication date | 2017-12-08 | |
| P1433 | published in | Pediatric Blood & Cancer | Q15754342 |
| P1476 | title | Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens | |
| P478 | volume | 65 | |